Vascepa icosapent ethyl regulatory update

Amarin disclosed in its 3Q13 earnings that it began the formal process to appeal FDA's rescission of an SPA for the biotech's Phase III ANCHOR trial, which evaluated Vascepa icosapent ethyl in combina...